Zheng Quan Zhi Xing·2025-08-22 10:21Group 1 - The board of directors of Rongchang Biopharmaceuticals held its 28th meeting, with all 9 directors present, confirming compliance with relevant laws and regulations [1][2] - The board approved the unaudited consolidated financial statements for the six months ending June 30, 2025, which were reviewed by the audit committee [1][3] - The board decided not to declare an interim dividend for 2025, considering the company's overall financial condition and capital needs [2][3] Group 2 - The board approved the company's 2025 interim report and its summary, ensuring compliance with regulations and confirming the accuracy and completeness of the information [2][3] - A special report on the use of raised funds for the first half of 2025 was also approved, with details available on the Shanghai Stock Exchange website [3][5] - The board reviewed and confirmed the effectiveness of the company's risk management and internal control systems for the first half of 2025 [4][5] Group 3 - The board confirmed compliance with the Corporate Governance Code and related rules, with no violations reported during the first half of 2025 [4][5] - An evaluation report on the "Quality Improvement and Efficiency Enhancement" action plan for 2025 was approved, summarizing the execution status for the first half of the year [4][5] - The board approved changes to the registered capital and amendments to the company's articles of association following the issuance of 19 million H shares on May 29, 2025 [5][6] Group 4 - The board reviewed the progress of the company's Environmental, Social, and Governance (ESG) goals for 2025, focusing on sustainable development and social responsibility [5][6]